Quick Answer
Bluejay Diagnostics, Inc. reported Stockholders Equity of $5.98 million for the year ending 2025.
- Bluejay Diagnostics, Inc. showed an increase of +4.3% in Stockholders Equity from 2024 to 2025.
- This data is from Bluejay Diagnostics, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$3.31 million | Q2 2020: -$3.55 million | Q3 2020: -$3.74 million | Q1 2021: -$4.30 million | Q2 2021: $123.5 thousand | Q3 2021: -$1.08 million | Q1 2022: $18.49 million | Q2 2022: $16.66 million | Q3 2022: $13.81 million | Q1 2023: $9.16 million | Q2 2023: $6.38 million | Q3 2023: $5.21 million | Q1 2024: $3.37 million | Q2 2024: $8.64 million | Q3 2024: $7.16 million | Q1 2025: $3.87 million | Q2 2025: $5.29 million | Q3 2025: $3.69 million.
- Over the full 7 years of available data (2019 to 2025), Bluejay Diagnostics, Inc.'s Stockholders Equity has grown by 303.8%.
- Historical annual values: Fiscal year 2025: $5.98 million | Fiscal year 2024: $5.73 million | Fiscal year 2023: $2.89 million | Fiscal year 2022: $11.54 million | Fiscal year 2021: $20.38 million | Fiscal year 2020: -$4.21 million | Fiscal year 2019: -$2.93 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: